[National Institutes of Health (NIH)](https://www.nih.gov/)

April 10, 2026

Awards range from $50,000 to $300,000 per year; estimated total program funding is $4,500,000; approximately 9 awards expected.

Supports advanced development and validation of emerging technologies to improve biospecimen analysis for basic and clinical cancer research.

--- ## Description This opportunity, issued by the National Cancer Institute (NCI), seeks applications for exploratory research projects focused on advancing and validating emerging technologies that offer new capabilities for targeting, probing, analyzing, handling, or performing quality control of biospecimens in basic or clinical cancer research. The goal is to further develop and rigorously validate technologies that have already overcome major feasibility barriers, as demonstrated by preliminary data, but still require additional work to enable broad adoption by the research community. Projects should aim to accelerate or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, or address cancer health disparities. Technologies must be focused on cancer applications, even if they have potential for broader use. Proposals that simply apply existing technologies to new biological or clinical questions, without technological innovation, will not be considered. This funding opportunity is part of the Innovative Molecular Analysis Technologies (IMAT) Program. --- ## Due Dates - Application Due Date: April 10, 2026 *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - Individual awards: $50,000 to $300,000 per year (direct costs) - Estimated total program funding: $4,500,000 - Expected number of awards: Approximately 9 - Project period: Typically 2–3 years (refer to the [program page](https://www.grants.gov/search-results-detail/360534) for details) --- ## Eligibility Eligible applicants include: - State, county, city, township, and special district governments - Independent school districts - Public and private institutions of higher education - Federally recognized and other Native American tribal governments and organizations - Public housing authorities and Indian housing authorities - Nonprofits with or without 501(c)(3) status (excluding institutions of higher education) - For-profit organizations (including small businesses) - U.S. territories and possessions - Eligible agencies of the federal government - Faith-based or community-based organizations - Regional organizations - Non-domestic (non-U.S.) entities (foreign institutions) - Others as defined in the [funding announcement](https://www.grants.gov/search-results-detail/360534) --- ## Application Process - Review the full Notice of Funding Opportunity (NOFO) on [Grants.gov](https://www.grants.gov/search-results-detail/360534). - Prepare a proposal demonstrating: - Preliminary data showing feasibility of the technology - Plan for further development and rigorous validation - Relevance to cancer research - Submit the application through the [Grants.gov portal](https://www.grants.gov/search-results-detail/360534) by the deadline. - No cost sharing or matching is required. --- ## Additional Information - Clinical trials are **not allowed** under this opportunity. - Projects must focus on technological innovation, not on the biological or clinical question alone. - This is an R33 mechanism; applicants should have preliminary data and evidence that major feasibility gaps have been overcome. --- ## External Links - [Funding Opportunity Announcement on Grants.gov](https://www.grants.gov/search-results-detail/360534) - [National Institutes of Health (NIH)](https://www.nih.gov/) --- ## Contact Information | Name | Email | Phone | |--------------------|-----------------------------|---------------| | Kelly Crotty, Ph.D.| Kelly.crotty@nih.gov | 240-255-0917 |

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Sign in to see full grant listing